The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

“They [create] significant clinical and public health challenges as well as the need for further research.” One author disclosed ties to Amgen and UBC.

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

The donation to Rush’s orthopedic department, the largest ever, creates four new endowed positions and programs.

Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...